Innrika 25/75/150 Mg 25 mg/ 75 mg /150 mg Capsule
PDF Leaflet Revision Date: 07/07/2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of neuropathic pain due to Herpes zoster and diabetes.
Dosage (summary)
Starting dose: 75 mg twice daily, may increase to 150 mg twice daily.
Special Populations
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- CNS depressants
- Opioids
Contraindications
- Hypersensitivity to pregabalin or excipients
Common side effects
- Dizziness
- Somnolence
- Blurred vision
Counselling Points
- Avoid driving until effects are known
- Monitor for signs of misuse or dependence
- Gradual discontinuation recommended
Serious warnings
- Risk of dependence
- Withdrawal symptoms
- Angioedema
Important Disclaimer
The Innrika 25/75/150 Mg 25 mg/ 75 mg /150 mg Capsule professional information leaflet below is the property of Innovata Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
